BIOT Awards | Industrial Biotechnology Award

Industrial Biotechnology Award

Background

This award is given biennially to honor organizations, companies, teams, or individuals for their achievements in the commercialization of novel processes exploiting biochemical technology. For this award, “processes” are broadly defined to include fully integrated processes to produce a biological product, technology that underlies or enables multiple processes, or processes that solve environmental problems (e.g. bioremediation). The inaugural award was made at the 1998 Fall meeting in Boston, MA.

The award consists of a commemorative plaque. The award ceremony takes place at the annual ACS meeting for which BIOT chooses to program and includes a presentation by a representative of the recipients on the design, development, and operation of the awarded process, with content as open as possible. All expenses associated with the receipt of the award, except for the plaque, are borne by the awardee(s).

Nomination

All nominations are conducted by self-nomination. This award is open to all organizations, companies, and teams, participating in the commercialization of novel processes exploiting biochemical technology. The novel process awarded must be a commercially practiced bioprocess technology and the award selection procedure will favor processes brought to commercial practice within the past 5 to 10 years.

In assessing the process that is the basis for a nomination, the selection committee will include in its consideration:

  1. Innovativeness of the process
  2. Innovativeness of the development path of the process
  3. Commercial and/or societal impact of the process
  4. Contribution of the process to advancing the state of the art in bioprocess technology as evidenced by patents, books, journal articles, or other forms of public disclosure

For further details and anonymous submissions, please go to acsbiot.submit.com.

Previous Awardees

  • 2024: Lanzatech
  • 2022: Moderna, Inc. Technical Development & CMC Organization
  • 2020: AstraZeneca Lumoxiti Process CMC Team
  • 2016: Merck for Keytruda
  • 2013: Regeneron
  • 2010: Cargill
  • 2009: DuPont/Genencor/Tate & Lyle for 1,3 propanediol process
  • 2008: Wyeth Platform for Process Development
  • 2007: Genetech Lucentis®
  • 2006: Merck for HPV
  • 2004: Bayer for Perfusion Technology
  • 2003: Advanced Tissue Sciences and IDEO for Dermagraft
  • 1998: Merck for VAQTA Vaccine